失眠症的治疗药物研究进展
The Development of Therapeutic Drugs for Insomnia
DOI: 10.12677/HJMCe.2017.51001, PDF, HTML, XML, 下载: 2,336  浏览: 5,839 
作者: 何华军, 沈喜洲：武汉工程大学化工与制药学院，湖北 武汉；王刚*, 刘亚军：北京信息技术研究所，北京；邵开元：北京神剑天军医学科学院，北京；胡文祥：武汉工程大学化工与制药学院，湖北 武汉；北京神剑天军医学科学院，北京
关键词: 失眠；苯二氮卓艹类；非苯二氮卓艹类；催眠药；作用机制；Insomnia； Benzodiazepine； Non-Benzodiazepine； Hypnotics； Mechanism
摘要: 近些年失眠患者不断增多，严重影响患者的心理和生理健康，人们对镇静催眠药物的需求越来越大。本文阐述了临床上使用最多的苯二氮䓬类镇静催眠药的发展历程，作用机制，构效关系及其常见副作用，介绍了近几年几种新型的非苯二氮䓬类药物，同时对于我国传统药物中药在治疗失眠上的作用进行概述，综合分析发现，开发药效更强，副作用更小的新型催眠药物将成为治疗失眠的主要发展方向。
Abstract: The number of patients with insomnia is continually increasing recently which has serious impact on their psychological and physiological health and in result people’s demand for sedative-hyp- notic is growing. In this paper, benzodiazepine which was widely used on clinic has been introduced, including its mechanism of action, pharmacokinetics, adverse reactions and development history, what’s more, several kinds of new non-benzodiazepine and our traditional Chinese medicine’s function on treating insomnia is introduced. Comprehensive analysis found that the combination of Chinese and Western treatment methods and new hypnotic drugs will become the main development direction of the treatment of insomnia.
文章引用：何华军, 王刚, 刘亚军, 沈喜洲, 邵开元, 胡文祥. 失眠症的治疗药物研究进展[J]. 药物化学, 2017, 5(1): 1-10. https://doi.org/10.12677/HJMCe.2017.51001

参考文献

[1] Wilson, S.J., Nutt, D.J., Alford, C., et al. (2010) British Association for Psychopharmacology Consensus Statement on Evi-dence-Based Treatment of Insomnia, Parasomnias and Circadian Rhythm Disorders. Journal of Psychopharmacology, 24, 1577-1601. https://doi.org/10.1177/0269881110379307
[2] 尹刘燕, 王兰芝, 李晓庆, 安迎双. 苯并[b][1,4]二氮杂䓬衍生物的合成及其应用新进展[J]. 有机化学, 2016(4): 711-723.
[3] Baldwin, D.S., Aitchison, K., Bateson, A., et al. (2013) Benzodiazepines: Risks and Benefits. A Reconsideration. Jour- nal of Psychopharmacology, 27, 967-971. https://doi.org/10.1177/0269881113503509
[4] Gouzer, G., Specht, C.G., Allain, L., et al. (2014) Benzodiazepine-Dependent Stabilization of GABA A Receptors at Synapses. Molecular and Cellular Neuroscience, 63, 101-113. https://doi.org/10.1016/j.mcn.2014.10.004
[5] Chanana, P. and Kumar, A. (2016) GABA-BZD Receptor Modulating Mechanism of Panaxquinquefolius against 72-h Sleep Deprivation Induced Anxiety like Behavior: Possible Roles of Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation. Frontiers in Neuroscience, 10, 84. https://doi.org/10.3389/fnins.2016.00084
[6] Preskorn, S.H. (2015) A Way of Conceptualizing Benzodiazepines to Guide Clinical Use. Journal of Psychiatric Practice, 21, 436-441. https://doi.org/10.1097/PRA.0000000000000114
[7] Saari, T.I., Uusi-Oukari, M., Ahonen, J., et al. (2011) Enhancement of GABAergic Activity: Neuropharmacological Effects of Benzodiazepines and Therapeutic Use in Anesthesiology. Pharmacological Reviews, 63, 243-267. https://doi.org/10.1124/pr.110.002717
[8] Mohsin, N.A. and Qadir, M.I. (2015) Recent Structure Activity Relationship Studies of 1, 4-Benzodiazepines. Peertechz Journal of Medicinal Chemistry and Research, 1, 12.
[9] Hadjipavlou-Litina, D., Garg, R. and Hansch, C. (2004) Comparative Quantitative Structure-Activity Relationship Studies (QSAR) on Non-Benzodiazepine Compounds Binding to Benzodiazepine Receptor (BzR). Chemical Reviews, 104, 3751-3794. https://doi.org/10.1021/cr0304469
[10] Cepanec, I., Litvic, M. and Pogorelic, I. (2006) Efficient Synthesis of 3-Hydroxy-1, 4-Benzodiazepines Oxazepam and Lorazepam by New Acetoxylation Reaction of 3-Position of 1, 4-Benzodiazepine Ring. Organic Process Research & Development, 10, 1192-1198. https://doi.org/10.1021/op068009u
[11] Filippakopoulos, P., Picaud, S., Fedorov, O., et al. (2012) Benzodiazepines and Benzotriazepines as Protein Interaction Inhibitors Targeting Bromodomains of the BET Family. Bioorganic & Medicinal Chemistry, 20, 1878-1886. https://doi.org/10.1016/j.bmc.2011.10.080
[12] Roehrs, T. and Roth, T. (2012) Insomnia Pharmacotherapy. Neurotherapeutics, 9, 728-738. https://doi.org/10.1007/s13311-012-0148-3
[13] Glass, J., Lanctot, K.L., Herrmann, N., et al. (2005) Sedative Hypnotics in Older People with Insomnia: Meta-Analysis of Risks and Benefits. British Medical Journal, 331, 1169-1176. https://doi.org/10.1136/bmj.38623.768588.47
[14] Lisko, B. and Pikalov, A. (2004) Zaleplon Overdose Associated with Sleepwalking and Complex Behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 43, 927-928. https://doi.org/10.1097/01.chi.0000129219.66563.aa
[15] Yang, W., Dollear, M. and Muthukrishnan, S.R. (2005) One Rare Side Effect of Zolpidem-Sleepwalking: A Case Report. Archives of Physical Medicine and Rehabilitation, 86, 1265-1266. https://doi.org/10.1016/j.apmr.2004.11.022
[16] Starcevic, V. (2014) The Reappraisal of Benzodiazepines in the Treatment of Anxiety and Related Disorders. Expert Review of Neurotherapeutics, 14, 1275-1286. https://doi.org/10.1586/14737175.2014.963057
[17] Kaur Gill, R., Om Kaushik, S., Chugh, J., et al. (2014) Recent Development in [1, 4] Benzodiazepines as Potent Anticancer Agents: A Review. Mini Reviews in Medicinal Chemistry, 14, 229-256. https://doi.org/10.2174/13895575113139990081
[18] Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A.A., Vennat, B., Llorca, P.M., et al. (2009) Benzodiazepine Dependence: Focus on Withdrawal Syndrome. Annales Pharmaceutiques Françaises, 67, 408-413. https://doi.org/10.1016/j.pharma.2009.07.001
[19] Rogin, J., Wheless, J., Abou-Khalil, B., et al. (2014) Safety and Effectiveness of Long-Term Treatment with Diazepam Auto-Injector Administered by Caregivers in an Outpatient Setting for the Treatment of Acute Repetitive Seizures. Epilepsia, 55, 1444-1451. https://doi.org/10.1111/epi.12685
[20] Kishore, K. and Singh, M. (2003) Effects of Triazolam and Flumazenil on Learning and Memory in Mice. Bio-Science Research Bulletin, 19, 41-46.
[21] Miyata, A., Iwamoto, K., Kawano, N., et al. (2015) The Effects of Acute Treatment with Ramelteon, Triazolam, and Placebo on Driving Performance, Cognitive Function, and Equilibrium Function in Healthy Volunteers. Psychopharmacology, 232, 2127-2137. https://doi.org/10.1007/s00213-014-3843-4
[22] Toshiki, M., Akira, B., Takumi, N. and Yasui, M. (2016) Quantification of Adverse Effects of Regular Use of Triazolam on Clinical Outcomes for Older People with Insomnia: A Retrospective Cohort Study. International Journal of Geriatric Psychiatry, 31, 186-194. https://doi.org/10.1002/gps.4310
[23] 骆泽宇. 佐匹克隆治疗失眠症的临床效果观察[J]. 广西医学, 2009, 31(06): 854-855.
[24] 王启娟, 蒋天华, 李成建. 唑吡坦所致睡行症文献概述[J]. 中国药物滥用防治杂志, 2014, 20(06): 361.
[25] 李洋, 曾训庭, 郑静波. 唑吡坦在中国的临床应用综述[J]. 上海医药, 2015(11): 26-28.
[26] 岳玲, 丁薇, 倪秀石. 唑吡坦治疗原发性失眠老年住院患者60例[J]. 中国临床保健杂志, 2015(04): 420-421.
[27] 王峥, 胡兴越. 扎来普隆治疗失眠症的临床评价[J]. 中国现代应用药学, 2017, 24(05): 369-372.
[28] Zlotos, D.P., Erikacecon, R., et al. (2014) MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers and Therapeutoc Potential. Journal of Medicinal Chemistry, 57, 3161-3185. https://doi.org/10.1021/jm401343c
[29] Roth, T., Stubbs, C. and Walsh, J.K. (2005) Ramelte-on(TAK-375), a Selective MT1/MT2-Receptor Agonist, Reduces Latency to Persistent Sleep in a Model of Transient Insomnia Related to a Novel Sleep Environment. Sleep, 28, 303-307.
[30] 周俊翔, 吴逢波, 唐尧. 雷美替胺治疗成人慢性失眠的系统评价[J]. 中国循证医学杂志, 2012, 12(3): 314-319.
[31] Kuriyama, A., Honda, M. and Hayashino, Y. (2014) Ramelteon for the Treatment of Insomnia in Adults: A Systematic Review and Meta-Analysis. Sleep Medicine, 15, 385-392. https://doi.org/10.1016/j.sleep.2013.11.788
[32] De Berardis, D., Marini, S., Fornaro, M., et al. (2013) Themelatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice. International Journal of Molecular Sciences, 14, 12458-12483. https://doi.org/10.3390/ijms140612458
[33] Grosshans, M., Mutschler, J., Luderer, M., et al. (2014) Agomelatine Is Effective in Reducing Insomnia in Abstinent Alcohol-Dependent Patients. Clinical Neuropharmacology, 37, 6-8. https://doi.org/10.1097/wnf.0000000000000007
[34] Teegarden, B.R., Li, H., Jayakumar, H., et al. (2010) Discovery of 1-[3-(4-Bromo-2-Methyl-2H-Pyrazol-3-yl)-4-Me- thoxyphenyl]-3-(2,4-Difluorophenyl)Urea (Nelotanserin) and Related 5-Hydroxytryptamine 2A Inverse Agonists for the Treatment of Insomnia. Journal of Medicinal Chemistry, 53, 1923-1936. https://doi.org/10.1021/jm9007328
[35] Griebel, G., Beeské, S., Jacquet, A., et al. (2013) Further Evidence for the Sleep-Promoting Effects of 5-HT 2A Receptor Antagonists and Demonstration of Synergistic Effects with the Hypnotic, Zolpidem in Rats. Neuropharmacology, 70, 19-26. https://doi.org/10.1016/j.neuropharm.2012.12.008
[36] 江连祥, 戴泽平. 食欲素能神经系统网络及其相互作用的生理功能[J]. 沈阳医学院学报, 2015, 17(04): 241-244.
[37] Snyder, E., Ma, J., Svetnik, V., et al. (2016) Effects of Suvorexant on Sleep Architecture and Power Spectral Profile in Patients with Insomnia: Analysis of Pooled Phase 3 Data. Sleep Medicine, 19, 93-100. https://doi.org/10.1016/j.sleep.2015.10.007
[38] 王维峰, 翟磊, 陈红云. 翟磊治疗失眠经验探析[J]. 亚太传统医药, 2015, 11(24): 83-84.
[39] 周丰宝, 杜翠翠. 中西医结合治疗顽固性失眠56例疗效观察[J]. 中国疗养医学, 2015, 24(3): 268-269.
[40] 郭秀翠. 一种治疗失眠的药用组合物[P]. 中国专利, 102847075, 2013-01-02.
[41] 李峰. 神宁汤联合曲唑酮治疗抑郁症伴发失眠随机平行对照研究[J]. 实用中医内科杂志, 2015, 29(11): 129-131.
[42] 沙中玮, 徐建. 失眠症的中西医治疗进展[J]. 东南国防医药, 2016, 18(2): 182-184.
[43] 康晓利. 针灸治疗失眠50例[J]. 内蒙古中医药, 2016, 35(03): 66-67.
[44] 罗丹, 李平. 李平教授治疗失眠经验介绍[J]. 光明中医, 2016, 31(8): 1072-1073.
[45] 何华军, 王刚, 刘亚军, 等. 苯二氮䓬类催眠药物三维定量构效关系研究[J]. 药物化学, 2016, 4(4): 25-37.